Engflag

Zoria

Quick links to important sections

Zoria

Zoria_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zoria

What is Zoria?

Zoria is a pharmacological treatment utilized in the management of glaucoma and ocular hypertension. It belongs to a class of medications known as prostaglandin analogs. These substances are synthetic versions of naturally occurring compounds in the body that play a role in regulating fluid dynamics within the eye.

Mechanism of Action

The primary function of Zoria is to reduce intraocular pressure. It achieves this by increasing the outflow of aqueous humor, the clear fluid produced inside the eye. When this fluid does not drain properly, pressure builds up, which can lead to progressive damage to the optic nerve.

Zoria specifically targets the uveoscleral pathway, an alternative drainage route for the aqueous humor. By enhancing the movement of fluid through this pathway, the medication helps maintain a stable internal eye pressure.

Clinical Application

Zoria is typically used for individuals diagnosed with conditions where eye pressure is higher than normal, including:

  • Open-Angle Glaucoma: A chronic condition where fluid drainage is gradually impaired, leading to potential vision loss if left untreated.
  • Ocular Hypertension: A state where intraocular pressure is elevated, but the optic nerve remains healthy and no vision loss has occurred yet.

Managing intraocular pressure is a key component in preventing the long-term complications associated with these conditions. Zoria is used to help keep these pressure levels within a range deemed appropriate by a healthcare professional.

What side effects are possible with Zoria?

Possible Side Effects and Safety Information

Zoria (roflumilast) is generally well-tolerated. The most commonly reported side effects across clinical trials (reported in ge 1% of patients) primarily affect the gastrointestinal and nervous systems. These common reactions include Diarrhea, Headache, Nausea, Insomnia, Nasopharyngitis, Upper respiratory tract infection, and Urinary tract infection. For topical formulations, Application site pain and, less commonly, Application site urticaria (hives) have also been reported.

Contraindications and Warnings

Hepatic Impairment: Zoria is contraindicated in patients who have moderate to severe liver impairment (Child-Pugh B or C), as the active ingredient is processed by the liver. Patients with any known or suspected liver problems should discuss this with a healthcare provider before use.

Flammability: The foam formulation contains flammable propellants. Users must avoid fire, flame, and smoking during and immediately following application.

Drug Interactions: Co-administration with strong inhibitors of the CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (such as specific antibiotics or antifungal medications) may increase Zoria's systemic exposure and potentially result in increased adverse reactions. Additionally, co-administration with oral contraceptives containing gestodene and ethinyl estradiol may also increase systemic exposure.

Special Populations:

  • The safety profile observed in pediatric patients (ages 6 or 9 years and older, depending on the formulation and indication) has been found to be generally consistent with that observed in adults.
  • While data on use in human pregnancy are limited, animal studies have shown that the active ingredient may disrupt the labor and delivery process and cause post-implantation loss or stillbirth at systemic exposures significantly higher than those achieved by the recommended human dose. Use during labor and delivery should be avoided.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents for Zoria Otic Solution detail specific manifestations and circumstances that require medical attention. Over-application in the ear may lead to localized signs of excessive use. Documented clinical presentations include the occurrence of persistent irritation, pain, or increased redness and swelling within the external auditory canal. If these local manifestations develop or fail to resolve after four days, discontinuation of the product and consultation with a healthcare professional are required.

The most serious overdose risk is related to accidental ingestion of the solution. If the product is swallowed, immediate action is necessary. Regulatory guidance explicitly mandates seeking immediate medical attention or contacting a Poison Control Center without delay, particularly concerning the pediatric population, for whom the risk of ingestion is a major consideration.

Treatment for both localized excessive use and accidental ingestion is strictly symptomatic and supportive, as no specific pharmacological antidote is known for this agent. In cases of significant accidental ingestion, hospital monitoring may be required to observe for potential systemic effects. The overdose profile is defined by these local and accidental exposure risks, which dictate the conditions under which urgent medical help must be sought.

Therapeutic Uses of Zoria

Quick Facts: Zoria Treatment Areas

  • Condition: Postpartum depression (PPD)
  • Therapeutic Action: Management of major depressive episodes in adults
  • Duration of Use: Prescribed as a brief course of therapy

What Zoria Treats: Main Uses and Benefits

Zoria (also known by its generic name, zuranolone) is a pharmaceutical product indicated for the treatment of postpartum depression (PPD) in adult patients. Postpartum depression is defined as a major depressive episode that occurs following childbirth, although symptoms may also begin during the later stages of pregnancy.

The primary therapeutic benefit of Zoria is the management of symptoms associated with PPD. A short, defined course of treatment is intended to lead to an improvement in depressive symptoms. This improvement may appear relatively quickly in some patients and be sustained for a period following the cessation of the 14-day treatment period.

The medication offers a specialized approach to treating this specific condition. It serves as an option in the care of individuals experiencing PPD, providing a way to address this health concern.

Eligibility and Restrictions for Use

Who Can and Cannot Use Zoria? Official Eligibility

The eligibility profile for Zoria (zuranolone) is defined by official regulatory documentation, primarily establishing use in the adult population and restricting its use based on physiological status and concomitant medications. The medicine is formally labeled for use only in adults (18 years and older) with Postpartum Depression.

Restrictions and Limitations

There are no absolute contraindications listed in the prescribing information, but the following restrictions apply:

  • Pregnancy: Use is restricted due to the potential for embryo-fetal harm. Females of reproductive potential must use effective contraception during treatment and for seven days after the final dose.
  • Concomitant Drugs: Use is prohibited when co-administered with strong CYP3A4 inducers, as this combination significantly reduces drug exposure, leading to a loss of effectiveness.
  • Organ Impairment: Patients with severe hepatic impairment or moderate to severe renal impairment are eligible only if they receive a specific, reduced dosage as noted in the official label.
  • Pediatric Use: Safety and effectiveness have not been established in patients under 18 years of age.
  • Lactation: Zuranolone is present in human milk, and use requires consideration of potential adverse effects on the breastfed child.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Zoria (zuranolone) is officially defined by its metabolic pathway and pharmacodynamic properties, resulting in specific requirements documented in regulatory labeling.

Pharmacokinetic Interactions

Category Regulatory Statement
Strong CYP3A Inducers Co-administration is avoided because it substantially reduces Zuranolone systemic exposure (AUC), which may reduce its efficacy.
Strong CYP3A Inhibitors Co-administration increases Zuranolone systemic exposure (AUC) by 62% and requires a modification to the Zuranolone dose as specified in the prescribing information.

Pharmacodynamic and Substance Interactions

Category Regulatory Statement
CNS Depressant Medicinal Products Co-administration with substances like opioids or benzodiazepines causes additive CNS depressant effects, including documented increased impairment in psychomotor performance.
Food, Alcohol, and Herbal Alcohol increases psychomotor impairment. Grapefruit products and St John’s Wort should be avoided due to their official classification as a CYP3A inhibitor and inducer, respectively.

Restrictions and Cautions

Timing-Based Restriction: Patients must be advised not to drive or engage in potentially hazardous activities until at least 12 hours after taking each dose, a formal restriction tied to the risk of CNS depressant effects.

Population-Specific Caution: Severe Hepatic Impairment results in increased systemic exposure to Zuranolone due to reduced clearance, as formally documented in regulatory labels.

Mechanism of Action

Chemical Disintegration of the Cerumen Matrix

The mechanism of Zoria is fundamentally a local chemical action driven by the active moiety, Hydrogen Peroxide ( H2 O2). Upon contact with moisture, the compound undergoes hydrolytic decomposition, releasing H2 O2 which immediately initiates the oxidation and solvent action against the lipid and protein bonds that form the dense structure of the earwax. This process directly targets the physical components of the cerumen matrix, which produces a change in the physical state of the cerumen, transitioning it toward lower viscosity.

Mechanical Fragmentation and Physical Detachment

Simultaneous with the solvent action is the physical consequence of the decomposition: the rapid release of nascent oxygen gas ( O2). This creates a localized, active effervescence (foaming) that exerts a mechanical force against the cerumen. This physical action serves to break the softened wax into smaller, dislodged fragments, ultimately resulting in the detachment of fragments from the external auditory canal wall.

Component Synergy for Enhanced Penetration

The mechanism's efficiency is supported by a synergistic action involving the Glycerin vehicle and the Urea component. The Glycerin acts as an emollient and penetrant, hydrating the wax and ensuring the active component reaches deep into the impaction before activation. The Urea provides a mild keratolytic effect, helping to break down the protein (keratin) components. This preparatory softening supports a more complete and efficient solvent and effervescent action across the entire wax mass.

Dosage and Administration Information

How to Use Zoria: Official Administration Guidelines

Zoria (zuranolone) is an oral medication administered as a capsule, and its usage is defined by a fixed, non-adjustable 14-day treatment course. The medicine is taken once daily in the evening, and its proper absorption requires administration with fat-containing food. The standard dosage regimen is 50 mg once daily.

Dosing and Course Structure

The full course of therapy is completed across 14 consecutive days; safety or effectiveness for re-treatment or use beyond this duration has not been established. In the event of a missed dose, the protocol is to skip that dose and take the next scheduled dose at the regular time the following evening, without taking extra capsules to compensate.

Population-Specific Use and Constraints

The treatment regimen involves specific dose reductions for certain patient populations. The dosage is reduced to 30 mg once daily for individuals with severe hepatic impairment (Child-Pugh C) or those with moderate or severe renal impairment (estimated GFR < 60 mL/min/1.73 m^2). This 30 mg dose is also utilized when Zoria is co-administered with a strong CYP3A4 inhibitor.

Furthermore, an administration constraint is placed on patient activity: individuals should not drive or engage in activities requiring complete mental alertness for at least 12 hours after each dose for the entire 14-day course.

Recent Clinical Evidence

Research evidence / Overview of Studies for Zoria (Zuranolone)

Evidence for Use in Postpartum Depression (PPD)

This section summarizes the structure of the key Randomized Controlled Trials (RCTs) and supporting studies that investigated the use of Zoria for the management of depressive episodes related to childbirth. It details the specific clinical scales and measurements (outcomes) used by researchers to assess changes in symptoms.

Research exploring Zoria's application in PPD was primarily conducted using highly controlled, short-term RCTs. These studies were designed to compare outcomes in participants receiving the medicine against outcomes in those receiving an inactive placebo. These formal trials are the type of evidence used to assess the medicine for regulatory approval. In these studies, research examined how symptoms evolved in the observed populations, and they specifically studied the change in the severity of depressive symptoms using a standardized tool called the 17-item Hamilton Depression Rating Scale (HAMD-17). This scale was used to measure symptom intensity, which includes features related to systemic or functional imbalance.

What the Pivotal Trials Studied

The main clinical trials included adult women diagnosed with a major depressive episode that began either in the final months of pregnancy or within four weeks after giving birth. To qualify for the pivotal studies, participants generally needed to have symptoms categorized as severe depression. The findings primarily describe patterns observed in these populations.

Duration of Effect and Follow-up Studies

The primary evidence is centered around the short-term observation period, with participants typically monitored up to Day 45 (about six weeks after the treatment started). This research examined short-term changes and how symptoms evolved in the observed populations during the period immediately following the cessation of the medicine. Longer follow-up durations were limited, meaning long-term effects are not fully established. Some open-label studies provide additional data regarding symptom patterns beyond the initial observation period.

Key Research Limitations and Uncertainties

While the core studies were rigorously conducted, comparative evidence is lacking for how this medicine was evaluated against established, longer-term antidepressant treatments also studied for PPD. Additionally, the follow-up durations were limited, and data for patients with milder PPD or those with certain high-risk co-occurring conditions remain insufficient due to trial exclusion criteria.

Frequently Asked Questions (FAQ)

Common questions about Zoria (FAQ)

Q: What are the most common side effects people report with Zoria?

A: Official patient information indicates that some common temporary side effects associated with Zoria use include a temporary foaming or crackling sound in the ear, a mild feeling of fullness, or a temporary slight decrease in hearing after using the drops. Mild itching inside the ear may also occur as the medication works.

Q: Does taking Zoria make you feel tired or drowsy?

A: Drowsiness is not a commonly reported side effect for Zoria (Carbamide Peroxide Otic Solution). However, regulatory information advises that if a person should experience dizziness, use should be stopped and consultation with a doctor is recommended.

Q: Are there any long-term side effects associated with Zoria use?

A: Regulatory warnings indicate that Zoria is intended for occasional use only. The product labeling advises against using it for more than four consecutive days, and if excessive earwax remains after that period, consultation with a healthcare provider is recommended.

Q: Does Zoria interact with common over-the-counter pain relievers?

A: Because Zoria is an ear drop solution applied locally, it is unlikely to interact with pain relievers or other oral medications taken orally. The primary caution is against using Zoria at the same time as other types of ear drops unless specifically directed by a healthcare professional.

Q: Can I take Zoria if I'm also taking a vitamin or herbal supplement?

A: To ensure safe use, official product information recommends consulting with a healthcare professional to confirm that Zoria is compatible with all other products being used concurrently, which includes any vitamins, supplements, or herbal remedies.

Q: Can Zoria be used by older adults?

A: Yes, Zoria (Carbamide Peroxide Otic Solution) is indicated for use by adults. Regulatory guidance for this product states it is appropriate for individuals over the age of 12.

Q: Is Zoria safe for children, and if so, at what ages?

A: The product is for use by children over 12 years of age. For children who are under the age of 12, the official label states that consultation with a doctor is recommended before use.

Q: Can men and women use Zoria for the same conditions?

A: Yes. Zoria is used to soften and remove excessive earwax in adults, and the indication for this use is not dependent on or restricted by gender.

Q: What if I accidentally miss a dose of Zoria?

A: If the product is being used on a regular schedule and a dose is missed, the dose is typically applied as soon as a person remembers. If it is already close to the time for the next scheduled dose, the missed one should be skipped, and the regular schedule resumed. Extra drops should not be used to compensate for a missed dose.

Q: Are there any natural remedies that should be avoided while on Zoria?

A: Official information advises consulting a doctor or pharmacist about any vitamins, supplements, or herbal products being used concurrently to confirm safe use alongside Zoria. This helps to avoid any potential unknown interactions.

Q: Can Zoria be taken with antacids?

A: Zoria is an ear drop solution used only in the ear, while antacids are taken orally. It is generally unlikely for orally consumed medications like antacids to interact with Zoria. However, it is always best practice to consult a healthcare provider about all medicines being used.

Q: What conditions make someone unable to use Zoria?

A: Use of Zoria is not recommended if a person has ear drainage or discharge, ear pain, dizziness, an injury or perforation (hole) of the eardrum, or has recently had ear surgery.

Q: Does Zoria affect my ability to drive or operate machinery?

A: While there is no specific driving restriction for this product, the label instructs users to stop use and consult a doctor if they experience dizziness. If dizziness occurs, it may be advisable to avoid operating a vehicle or machinery until the dizziness resolves.

Q: Are there different strengths or forms of Zoria available (e.g., tablet, liquid)?

A: The most common form of Zoria is an Otic Solution (liquid drops). The active ingredient, Carbamide Peroxide, is typically supplied over-the-counter as a 6.5% concentration for earwax removal.

Q: Where does Zoria fit into the typical treatment plan for its main indication?

A: Zoria is designed to soften, loosen, and remove excessive earwax. It may be used as a preparatory step, or aid, prior to a secondary method of removal, such as gently flushing the ear with warm water.

Q: Is Zoria a medication I will need to take forever?

A: No. Zoria is a product for temporary, occasional use only. The official labeling warns against using it for more than four consecutive days, and consultation with a healthcare professional is recommended if the issue persists.

Q: What should I do if my symptoms get worse after starting Zoria?

A: If symptoms worsen or if new symptoms such as irritation or pain develop while using Zoria, it is advised to stop using the product and seek consultation with a doctor.

Q: Why do some people say Zoria didn't work for them?

A: The official product instructions advise that if excessive earwax remains or is not sufficiently removed after using the product for four days, consultation with a doctor is advised. The product may not be effective for all degrees of impaction.

Q: What age group has the best results with Zoria?

A: Zoria is officially labeled for use in adults and children over 12 years of age. Effectiveness has not been established for younger pediatric patients.

Q: Is Zoria considered a high-risk medication?

A: Zoria is classified as an Over-the-Counter (OTC) medication, but official warnings state it must not be used if specific pre-existing ear conditions such as a perforated eardrum or ear pain are present, as this could lead to complications.

Q: Are there specific times of day Zoria should be taken?

A: Typical directions advise using the product twice daily for up to four consecutive days.

Q: What are the typical benefits people experience after starting Zoria?

A: The primary expected benefits are the softening, loosening, and effective removal of excessive or hardened earwax, thereby relieving associated discomfort.

Q: Does Zoria have a generic version available yet?

A: Yes. Zoria's active ingredient, Carbamide Peroxide 6.5%, is covered by an FDA OTC Monograph and is widely available under various generic brand names.

Q: Why is Zoria sometimes used in combination with other treatments?

A: Zoria acts as an aid to prepare the earwax for removal. The label instructs that any wax remaining after treatment may be gently removed by flushing the ear with warm water using an ear syringe, indicating its role as a precursor to physical removal.

Q: What are some less common but possible side effects of Zoria?

A: Serious side effects, though rare for this type of product, may include signs of an allergic reaction such as rash, hives, or swelling. If a person experiences worsening ear pain, or any signs of severe reaction, immediate medical attention should be sought.

Q: Can Zoria be used during pregnancy or while breastfeeding?

A: If a person is pregnant or currently breastfeeding, consultation with a healthcare professional is necessary before using Zoria to ensure appropriate use.

How should Zoria be stored and disposed of?

How to Store and Dispose of Zoria (Zuranolone)

Zoria capsules must be stored according to regulatory requirements to ensure stability and safety.

Storage Conditions

Requirement Specific Instruction
Temperature Store at controlled room temperature: 20 C to 25 C (68 F to 77 F), with excursions permitted between 15 C and 30 C (59 F and 86 F).
Protection Keep from freezing, moisture, and direct light.
Child Safety Due to its classification as a Schedule IV controlled substance, keep this medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Zoria must be handled according to controlled substance disposal protocols. It is not recommended to dispose of the capsules by flushing. The official procedure is to use a drug take-back program or follow authorized household disposal rules, such as mixing the product with an undesirable substance and discarding it in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTaiwan

Equivalent of Zoria found in:

A-Z Index: